BAC
Bank of America Corporation
BAC has a slight edge over BSRR overall, supported by stronger valuation and stronger modeled upside.
BSRR
Sierra Bancorp
BSRR's outlook is improving, though it still trails on the overall score.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
BSRR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
BSRR's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like BSRR.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over BSRR in the historical PE scenario, which offers more potential upside but is not a forecast.
BSRR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.1x | $31.30 | -26% |
| Fair | 9.4x | $36.40 | -13% |
| Current | 11x | $42.06 | — |
| Forward | 11x | $42.06 | — |
| Expensive | 12x | $45.12 | +7.3% |
Historical ranges are pointers, not guarantees.
BSRR's PE is in its expensive range at 10.9x. On analysts' estimates for next year's earnings, today's price would be 10.9x.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over BSRR on the outlook, with more favorable valuation and revenue expectations.
BSRR Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect BSRR's earnings to grow and its profitability to improve, with its revenue holding steady.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over BSRR on earnings, with stronger typical year-over-year growth.
BSRR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.87 | -0.1% |
| Q3 2026 | $3.87 | +35% |
| Q2 2026 | $3.41 | +18% |
| Q1 2026 | $3.42 | +21% |
| Q4 2025 | $3.11 | +11% |
| Q3 2025 | $2.87 | +14% |
| Q2 2025 | $2.89 | +17% |
| Q1 2025 | $2.82 | +17% |
| Q4 2024 | $2.81 | +19% |
BSRR's earnings per share have climbed steadily: $3.87 over the past year, up 35% from the year before, and higher year over year for 13 quarters in a row.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over BSRR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
BSRR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $40.1M | +0.1% |
| Q2 2026 | $39M | -0.6% |
| Q1 2026 | $38.6M | +5% |
| Q4 2025 | $39.3M | +3.8% |
| Q3 2025 | $40M | +3.8% |
| Q2 2025 | $39.2M | +3.7% |
| Q1 2025 | $36.8M | -1.5% |
| Q4 2024 | $37.9M | +5.4% |
BSRR's revenue grew through 2024 and has held roughly level since: $40M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 49% | +18 points |
| Q2 2026 | 34% | -2.3 points |
| Q1 2026 | 43% | +10 points |
| Q4 2025 | 44% | +10 points |
| Q3 2025 | 32% | -5.6 points |
| Q2 2025 | 36% | -1.3 points |
| Q1 2025 | 33% | -0.6 points |
| Q4 2024 | 33% | +10 points |
BSRR has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
BSRR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20.7M | +41% |
| Q2 2026 | $5.4M | +$41.7M |
| Q1 2026 | $11M | -73% |
| Q4 2025 | $13.5M | -38% |
| Q3 2025 | $14.7M | -46% |
| Q2 2025 | -$36.3M | -18076% |
| Q1 2025 | $40.2M | +509% |
| Q4 2024 | $21.9M | +437% |
BSRR's free cash flow was $51M over the past year, up 25% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BSRR.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over BSRR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
BSRR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -35.6K shares |
| 1 year | -4.1% | -547K shares |
| 3 years | -12% | -1.7M shares |
| 5 years | -16% | -2.4M shares |
| Available history | -16% | -2.5M shares |
BSRR has 13M diluted shares, down 4.1% from a year ago, with $22M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $5M |
| Q1 2026 | $9.9M |
| Q4 2025 | $7.5M |
| Q3 2025 | $6M |
| Q2 2025 | $4M |
| Q1 2025 | $14.3M |
| Q4 2024 | $7.2M |
BSRR spent $22M buying back its own shares over the past year, down 29% from the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
BSRR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -1.8x | Net Cash |
| Q4 2025 | 4.7x | High |
| Q3 2025 | -0.9x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | 1.1x | Healthy |
BSRR has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
BSRR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.1 | Neutral |
| Stochastic | 60.4 | Neutral |
BSRR's weekly RSI is 62 (neutral) and its Stochastic is 60 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
BSRR PE vs Financial Services Sector
| Metric | BSRR | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 13x | 17% below |
| PE % | 71 | 63 | 8 pts above |
BSRR has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
BSRR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $40.7 | 3.4% above |
| 20 week MA | $40.8 | 3.2% above |
| 50 week MA | $37.9 | 11% above |
| 100 week MA | $33.4 | 26% above |
| 200 week MA | $27.5 | 53% above |
BSRR has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
BSRR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.2 | $23.6 | -19% |
| 2021 | $23.6 | $27.3 | +16% |
| 2022 | $27.3 | $21.7 | -21% |
| 2023 | $21.7 | $22.6 | +4% |
| 2024 | $22.6 | $29.0 | +29% |
| 2025 | $29.0 | $33.1 | +14% |
| 2026 YTD | $33.1 | $42.1 | +27% |
BSRR has the edge over BAC on returns for 2026, with the stronger performance.